Investor Presentation

Pro forma sales and EBITDA development Strong LTM Q3-2019 sales performance topped up with additional growth from acquisitions and continued trend of increasing EBITDA through strategic initiatives and further accelerated by acquisitions EURM PRO FORMA SALES LTM Q3-2019 9.4% 20.7 677.3 37.3 656.6 619.3 EURM 53.0 1.5 PRO FORMA EBITDA LTM Q3-2019 42.6% 4.0 75.6 17.1 71.6 Reported Sales 2018 Acquired & Organic growth Reported sales LTM Q3-2019 Full-year PF effect PF Sales LTM Q3-2019 Adjusted EBITDA 2018 Acquired & Organic growth IFRS 16 Impact Adjusted EBITDA LTM Q3-2019 Full-year PF effect PF Adjusted EBITDA LTM Q3-2019 Commentary Sales attributed to acquisitions over the period amounted to EUR 30.2m and organic sales contribution amounted to EUR 7.0m, with the rest relating to FX impact Majority of pro forma sales comes from The Plastic Surgeon in the UK, Alvisa24 in Switzerland and Tehokuivaus in Finland Commentary Adj. EBITDA has been impacted by the change in accounting standards, but grew over the period on a like-for-like basis Majority of pro forma effect on EBITDA comes from The Plastic Surgeon, Alvisa24 and Tehokuivaus Effects on EBITDA from the acquisition of AM Restore and Nettag will be positive in Q4 2019 Note: For LTM calculations please see Reconciliation tables (p. 44-45), Pro forma adjustments consist of contribution from acquisitions Source: Company information FINANCIAL DEVELOPMENT | POLYGON 22

View entire presentation